| Autor: |
Zheng, Jack Jingyuan, Hong, Brian V., Agus, Joanne, Tang, Xinyu, Guo, Fei, Lebrilla, Carlito B., Harvey, Danielle J., Jin, Lee‐Way, Maezawa, Izumi, Zivkovic, Angela M. |
| Zdroj: |
Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Dec2023 Supplement 23, Vol. 19, p1-1, 1p |
| Abstrakt: |
Background: High‐density lipoproteins (HDL) are protective against several chronic diseases, including Alzheimer's disease (AD). The size distribution of HDL particles is one of the determining factors of HDL function since HDL of various sizes subgroups play unique roles. Yet not much is known about HDL particle size distribution in the context of AD. Method: In this study negative‐stained transmission electron microscopy (NS‐TEM) was used to explore the particle size distribution of isolated HDL samples from 194 subjects with AD (n = 71), mild cognitive impairment (MCI, n = 40), or no cognitive impairment (n = 83). HDL particles were isolated using density‐adjusted ultracentrifugation followed by size exclusion chromatography and analyzed by NS‐TEM followed by image analysis using the software ImageJ. Individual particle diameter data were obtained, grouped into different size‐based categories and the relative abundances of each subgroup were compared among diagnostic groups and across clinical parameters. Result: Patients with AD and MCI had a significantly higher percentage of 7‐8 nm HDL particles and a lower percentage of 9‐10 nm, 12‐13 nm, and 13‐14 nm particles. Body mass index, clinical dementia rating score, and white matter hyperintensity volume were positively correlated with the percentage of 7‐8 nm particles and negatively correlated with the percentage of 9‐10 nm particles, whereas executive score, semantic memory score, and verbal memory score were negatively correlated with the percentage of 7‐8 nm particles, and positively correlated with the percentage of 9‐10 nm particles. Conclusion: These findings show that specific alterations in HDL particle size distribution in patients with AD and MCI are linked with measures of cognitive function and may be a promising direction for the discovery of new biomarkers and therapeutic targets in AD. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
